Mon, Jun 30, 2025
1- , s.meh.jafari@goums.ac.ir
Abstract: (189 Views)
Background: Gastric cancer (GC) is one of the widespread gastrointestinal tumors in the worldwide, with mortality rates among the highest. In the world, we face more than one million newly diagnosed stomach cancer patients every year. Various factors closely associated with formation of GC. One of these factors is the change in the level of components of the extracellular matrix in the microenvironment of the stomach tumor. Fibulins are one of the secreted glycoproteins of extracellular matrix, which are known as matrix organizers. The purpose of this study is to investigate the changes in fibulins in gastric tumor tissue compared to control samples.
Methods: Scopus, PubMed, and Web of Science databases were searched for articles that examined FBLN gene family and protein expression in patients with gastric cancer and gastric cancer cell lines.
Results: A total of 853 gastric cancer tumor samples, ranging from 8 to 197 per study, were analyzed across eight studies published between 2008 and 2023, all conducted in China. Several gastric cancer cell lines were also included, such as AGS, Kato III, MKN28, MKN45, SNU1, SNU16, NCI-N87, MGC-803, BGC-823, SGC-7901, and HGC27. Tumor size was reported in 4 studies, while histopathological grade and lymph node metastasis were each evaluated in 4 studies.
Conclusion: The downregulation of Fibulin-1 and Fibulin-2 supports their potential tumor-suppressive roles in gastric cancer, while the upregulation of Fibulin-5 is associated to tumor progression and worse prognosis, making it a candidate biomarker for aggressive disease.
Methods: Scopus, PubMed, and Web of Science databases were searched for articles that examined FBLN gene family and protein expression in patients with gastric cancer and gastric cancer cell lines.
Results: A total of 853 gastric cancer tumor samples, ranging from 8 to 197 per study, were analyzed across eight studies published between 2008 and 2023, all conducted in China. Several gastric cancer cell lines were also included, such as AGS, Kato III, MKN28, MKN45, SNU1, SNU16, NCI-N87, MGC-803, BGC-823, SGC-7901, and HGC27. Tumor size was reported in 4 studies, while histopathological grade and lymph node metastasis were each evaluated in 4 studies.
Conclusion: The downregulation of Fibulin-1 and Fibulin-2 supports their potential tumor-suppressive roles in gastric cancer, while the upregulation of Fibulin-5 is associated to tumor progression and worse prognosis, making it a candidate biomarker for aggressive disease.
Research Article: Systematic Review |
Subject:
Biochemistry
Received: 2024/08/17 | Accepted: 2024/11/26
Received: 2024/08/17 | Accepted: 2024/11/26
References
1. Nie W, Hu L, Yan Z, Wang Y, Shi Q, He S, et al. A potential therapeutic approach for gastric cancer: inhibition of LACTB transcript 1. Aging (Albany NY). 2023;15(24):15213-27. [View at publisher] [DOI] [PMID] [Google scholar]
2. Xuan J, Li F, Li J, Gong C, Li J, Mo Z, et al. The role of senescence genes in the treatment, prognosis, and tumor microenvironment of gastric cancer. Am J Transl Res. 2023;15(12):6926-38. [View at publisher] [PMID] [Google scholar]
3. Liu Z, Yang M, Shu H, Zhou J. A novel prognostic and therapeutic target biomarker based on complement-related gene signature in gastric cancer. Transl Cancer Res. 2023;12(12):3565-80. [View at publisher] [DOI] [PMID] [Google scholar]
4. Kawada J, Saito T, Kurokawa Y, Kawabata R, Takeno A, Takeoka T, et al. Serum NY-ESO-1 and p53 antibodies as useful tumor markers in gastric cancer. Ann Gastroenterol Surg. 2023;8(2):243-50. [View at publisher] [DOI] [PMID] [Google scholar]
5. Wroblewski LE, Peek jr RM. Clinical Pathogenesis, Molecular Mechanisms of Gastric Cancer Development. Curr Top Microbiol Immunol. 2023;444:25-52. [View at publisher] [DOI] [PMID] [Google scholar]
6. Guo M, Hu P, Xie J, Tang K, Hu S, Sun J, et al. Remodeling the immune microenvironment for gastric cancer therapy through antagonism of prostaglandin E2 receptor 4. Genes Dis. 2024;11(4):101164. [View at publisher] [DOI] [PMID] [Google scholar]
7. Feng L, Yao C, Li P, Feng Y, Wang F, Liu YF, et al. Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer. Tumour Biol. 2016;37(7):9399-410. [View at publisher] [DOI] [PMID] [Google scholar]
8. Gong J, Jie Y, Xiao C, Zhou W, Li X, Chen Y, et al. Increased Expression of Fibulin-1 Is Associated With Hepatocellular Carcinoma Progression by Regulating the Notch Signaling Pathway. Front Cell Dev Biol. 2020;8:478. [View at publisher] [DOI] [PMID] [Google scholar]
9. Li R, Wu H, Jiang H, Wang Q, Dou Z, Ma H, et al. FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma. Oncol Rep. 2020;44(5):2143-51. [View at publisher] [DOI] [PMID] [Google scholar]
10. Li WM, Chan TC, Huang SK, Wu WJ, Ke HL, Liang PI, et al. Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma. Front Oncol. 2020;10:570340. [DOI] [PMID] [Google scholar]
11. Hang Pham LB, Yoo YR, Park SH, Back SA, Kim SW, Bjørge I, et al. Investigating the effect of fibulin-1 on the differentiation of human nasal inferior turbinate-derived mesenchymal stem cells into osteoblasts. J Biomed Mater Res A. 2017;105(8):2291-8. [View at publisher] [DOI] [PMID] [Google scholar]
12. Sang Y, Mao KM, Huang Y, Wu XF, Wang XF, Ruan L, et al. Relationship between the Plasma Fibulin-1 Levels, Pulse Wave Velocity, and Vascular Age in Asymptomatic Hyperuricemia. Curr Med Sci. 2021;41(1):94-9. [View at publisher] [DOI] [PMID] [Google scholar]
13. Scarinci E, Tropea A, Russo G, Notaristefano G, Messana C, Alesiani O, et al. Increased fibulin-1 plasma levels in polycystic ovary syndrome (PCOS) patients: possible contribution to the link between PCOS and cardiovascular risk. J Endocrinol Invest. 2019;42(1):91-6. [View at publisher] [DOI] [PMID] [Google scholar]
14. Watany MM, Elmashad NM, Badawi R, Hawash N. Serum FBLN1 and STK31 as biomarkers of colorectal cancer and their ability to noninvasively differentiate colorectal cancer from benign polyps. Clin Chim Acta. 2018;483:151-5. [View at Publisher] [DOI] [PMID] [Google Scholar]
15. Jie Y, Gong J, Xiao C, Zheng J, Zhang Z, Li X, et al. The clinical value of Fibulin-1 for prognosis and its prospective mechanism in intrahepatic cholangiocarcinoma. HPB (Oxford). 2019;21(4):499-507. [View at Publisher] [DOI] [PMID] [Google Scholar]
16. Ustunyurt E, Dundar B, Simsek D, Temur M. Act of fibulin-1 in preeclamptic patients: can it be a predictive marker? J Matern Fetal Neonatal Med. 2021;34(22):3775-81. [View at Publisher] [DOI] [PMID] [Google Scholar]
17. Gao Y, Chen T, Hong L. Fibulin-1 promotes intimal hyperplasia after venous stent implantation through ACE mediated angiotensin II signaling. Heliyon. 2024;10(7):e27626. [View at Publisher] [DOI] [PMID] [Google scholar]
18. Ma Y, Nenkov M, Schröder DC, Abubrig M, Gassler N, Chen Y. Fibulin 2 Is Hypermethylated and Suppresses Tumor Cell Proliferation through Inhibition of Cell Adhesion and Extracellular Matrix Genes in Non-Small Cell Lung Cancer. Int J Mol Sci. 2021;22(21):11834 [View at Publisher] [DOI] [PMID] [Google scholar]
19. Ibrahim AM, Sabet S, El-Ghor AA, Kamel N, Anis SE, Morris JS, et al. Fibulin-2 is required for basement membrane integrity of mammary epithelium. Sci Rep. 2018;8(1):14139. [View at Publisher] [DOI] [PMID] [Google Scholar]
20. Zhang M, Chen F, Feng S, Liu X, Wang Z, Shen N, et al. FBLN5 as One Presumably Prognostic Gene Potentially Modulating Tumor Immune Microenvironment for Renal Clear Cell Carcinoma in Children and Young Adults. Pharmgenomics Pers Med. 2024;17:27-40. [View at Publisher] [DOI] [PMID] [Google Scholar]
21. Li Y, Yang X, Lu D. Knockdown of ubiquitin-conjugating enzyme E2T (UBE2T) suppresses lung adenocarcinoma progression via targeting fibulin-5 (FBLN5). Bioengineered. 2022;13(5):11867-80. [View at Publisher] [DOI] [PMID] [Google Scholar]
22. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280-6. [View at Publisher] [DOI] [PMID] [Google Scholar]
23. Feng L, Yao C, Li P, Feng Y, Wang F, Liu YF, et al. Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer. Tumor Biology. 2016;37(7):9399-410. [View at Publisher] [DOI] [PMID] [Google Scholar]
24. Cheng YY, Jin H, Liu X, Siu JMT, Wong YP, Ng EKO, et al. Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. British Journal of Cancer. 2008;99(12):2083-7. [View at Publisher] [DOI] [PMID] [Google scholar]
25. Ma HP, Lian CH, Song Y. Fibulin-2 inhibits development of gastric cancer by downregulating β-catenin. Oncol Lett. 2019;18(3):2799-804. [View at Publisher] [DOI] [PMID] [Google Scholar]
26. Shen K, Xia W, Wang K, Li J, Xu W, Liu H, et al. ITGBL1 promotes anoikis resistance and metastasis in human gastric cancer via the AKT/FBLN2 axis.J Cell Mol Med. 2024;28(4):e18113. [View at Publisher] [DOI] [PMID] [Google scholar]
27. Wang X, Zhi Q, Liu S, Xue SL, Shen C, Li Y, et al. Identification of specific biomarkers for gastric adenocarcinoma by ITRAQ proteomic approach. Sci Rep. 2016;6:38871. [View at Publisher] [DOI] [PMID] [Google scholar]
28. Leng X, Yang C, Xiong B, Hou J. Increased expression of Fibulin-5 in gastric cancer associated with poor prognosis. Int J Clin Exp Med. 2016;9(10):19725-32. [View at Publisher] [Google Scholar]
29. Shi XY, Wang L, Cao CH, Li ZY, Chen J, Li C. Effect of Fibulin-5 on cell proliferation and invasion in human gastric cancer patients.Asian Pac J Trop Med. 2014;7(10):787-91. [View at Publisher] [DOI] [PMID] [Google Scholar]
30. Chen T, Li D, Wang Y, Shen X, Dong A, Dong C, et al. Loss of NDUFS1 promotes gastric cancer progression by activating the mitochondrial ROS-HIF1α-FBLN5 signaling pathway. Br J Cancer. 2023;129(8):1261-73. [View at Publisher] [DOI] [PMID] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.